9.62
Anteris Technologies Global Corp stock is traded at $9.62, with a volume of 2.34M.
It is up +6.89% in the last 24 hours and up +69.07% over the past month.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
See More
Previous Close:
$9.00
Open:
$9.03
24h Volume:
2.34M
Relative Volume:
2.47
Market Cap:
$936.43M
Revenue:
$1.91M
Net Income/Loss:
$-94.23M
P/E Ratio:
-3.7718
EPS:
-2.5505
Net Cash Flow:
$-79.76M
1W Performance:
+32.87%
1M Performance:
+69.07%
6M Performance:
+173.30%
1Y Performance:
+197.83%
Anteris Technologies Global Corp Stock (AVR) Company Profile
Name
Anteris Technologies Global Corp
Sector
Industry
Phone
651-493-0606
Address
860 BLUE GENTIAN ROAD, EAGAN
Compare AVR vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
AVR
Anteris Technologies Global Corp
|
9.62 | 876.08M | 1.91M | -94.23M | -79.76M | -2.5505 |
|
ISRG
Intuitive Surgical Inc
|
438.10 | 155.76B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
BDX
Becton Dickinson Co
|
147.63 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
67.78 | 33.13B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
37.01 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
208.05 | 30.31B | 5.54B | 1.52B | 1.74B | 10.37 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-11-26 | Initiated | Wells Fargo | Overweight |
| Jan-08-25 | Initiated | Lake Street | Buy |
| Jan-07-25 | Initiated | Barclays | Overweight |
| Jan-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
View All
Anteris Technologies Global Corp Stock (AVR) Latest News
Anteris Technologies Global Corp plans to issue up to $250 million in common stock through TD Cowen as the underwriter. - Bitget
Anteris Technologies Global Launches $250 Million ATM Offering Under Sales Agreement With TD Cowen - TradingView
Anteris (NASDAQ: AVR) launches $250M at-the-market share program - Stock Titan
Anteris Technologies (NASDAQ: AVR) establishes $250M ATM with TD Cowen - Stock Titan
ChartWatch ASX Scans: Brazilian Rare Earths, Echoiq, Weebit Nano. Anteris Technologies, Global X Semiconductor ETF - Market Index
Anteris Technologies Global : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Director Susan Knight reports initial insider status at Anteris (NASDAQ: AVR) - Stock Titan
Number of shareholders of Anteris Technologies Global Corp. – NASDAQ:AVR - TradingView
Nantahala holds 6,143,154 shares of Anteris (AVR) as of 03/31/2026 - Stock Titan
AVR Maintained by Barclays -- Price Target Raised to $18.00 - GuruFocus
Anteris Technologies Global Corp. (AVR) Gets a Buy from TD Cowen - The Globe and Mail
Anteris Announces Results for the First Quarter of 2026 - Sahm
Anteris Technologies Adds Experienced Financial Leaders to Board - The Globe and Mail
TradingKey - TradingKey
Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation - Yahoo Finance
How Should Investors Value Anteris Technologies Global Corp (AVR - GuruFocus
Anteris Technologies appoints two directors to board - Investing.com
Anteris Technologies appoints two directors to board By Investing.com - Investing.com South Africa
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors - The Manila Times
Two experienced directors join Anteris as it advances DurAVR heart valve - Stock Titan
Anteris Technologies Reports Q1 2026 Results: $320M Raised and Key Milestones in PARADIGM Trial for DurAVR THV System - Minichart
Anteris Technologies Global Corp. Files Form 8-K for Nasdaq Listing and Company Details (May 12, 2026) - Minichart
Anteris Technologies Global adds Susan Knight and Stephen Denaro to board - Investing.com
Anteris Technologies Global Starts US PARADIGM Trial Enrolment - smallcaps.com.au
Anteris Technologies Posts Narrower Q1 Loss, Lower Net Sales - Moomoo
Why Market Is Bullish on Anteris Technologies (ASX:AVR) Today - Kalkine
Anteris adds seasoned finance leaders to board as structural heart push continues - TipRanks
Anteris Technologies Q1 2026 Results: DurAVR™ THV Trial Progresses, Cash Balance at $64.9 Million - geneonline.com
Anteris Technologies Global Corp reports results for the quarter ended March 31Earnings Summary - TradingView
AVR: DurAVRⓇ THV system adoption grows, with Q1 2026 payments to related parties at US$2.3M - TradingView
Anteris Technologies Global Corp. 1Q 2026: Revenue $494K, EPS ($0.28) — 10-Q Summary - TradingView
Anteris Technologies (Nasdaq: AVR) posts Q1 2026 loss, raises $320M for DurAVR trial - Stock Titan
Anteris Technologies Global Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Anteris Technologies Global Corp at Barclays Global Healthcare Conference Transcript - GuruFocus
Anteris Technologies Global Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances | ASX:AVR, NASDAQ:AVR - Proactive financial news
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances - Yahoo Finance
Anteris Technologies Enrolls First US Patients in PARADIGM Trial; Shares Up 6% - marketscreener.com
First U.S. patients enrolled in Anteris heart valve trial By Investing.com - Investing.com South Africa
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial - The Manila Times
Anteris Technologies begins U.S. enrollment in heart valve trial - StreetInsider
First U.S. patients enter Anteris heart valve trial for stenosis - Stock Titan
Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (AVR) and Siemens Healthineers AG (OtherSEMHF) - The Globe and Mail
Anteris Sees CDI Decline as Investors Shift to Nasdaq-Listed Common Stock - TipRanks
Sio Capital (AVR) reports 5.38M shares, 5.54% stake as of Mar 31, 2026 - Stock Titan
AVR Stock Price, Quote & Chart | ANTERIS TECHNOLOGIES GLOBAL (NASDAQ:AVR) - ChartMill
Anteris Ends v2vmedtech Development Agreement, Limits Exposure - The Globe and Mail
Anteris Technologies Global Corp. (NASDAQ: AVR) registers 9.10M shares; discontinues v2v contributions - Stock Titan
Anteris Technologies Exits v2vmedtech Development Agreement, to Pay $400,000 Break Fee, Shares Up 3% - marketscreener.com
Anteris Technologies Exits V2vmedtech Development Agreement, to Pay $400,000 Break Fee, Shares Up 3% - 富途牛牛
Anteris Walks Away From v2vmedtech Funding Deal With Limited Financial Impact - TipRanks
Anteris Technologies Global Corp Stock (AVR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):